Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

Marco Colleoni, C. Graiff, G. Vicario, P. Nelli, G. Sgarbossa, F. Pancheri, P. Manente

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy. Encouraging results have been reported in Phase II studies with estramustine associated with vinblastine or etoposide. Vinorelbine is a new semisynthetic vinca alkaloid that has demonstrated activity in prostate cancer. We therefore evaluated the activity of the following schedule: estramustine, 400 mg/m2 orally days 1-42; etoposide, 50 mg/m2 orally days 1-14; and 28-42; vinorelbine, 20 mg/m2 days 1, 8, 28, and 35; cycles being repeated every 8 weeks. Twenty-five patients have been included and are assessable for response and side effects. Patient characteristics were as follows: median age, 71 years (range 55-81); ECOG performance status 0-2; nonosseous disease, 3 cases; bone metastases, 23 cases. Sixty-two cycles have been delivered. Two patients with measurable disease and six patients with bone disease had a partial remission for an overall response rate of 32% (95% confidence interval 15-53%). Seven patients had stabilization of disease and 10 had progression of disease. Median duration of response was 3 months (range 2-5). Prostate-specific antigen in 14 patients (56%) decreased from baseline by at least 50%. Toxicity was manageable. Neutropenia was mild, with only three cases of grade Ill-IV toxicity. Two patients had severe anemia. The results of this study indicate that the schedule is active and well tolerated in hormone-refractory prostate cancer patients.

Original languageEnglish
Pages (from-to)383-386
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume20
Issue number4
DOIs
Publication statusPublished - Aug 1997

Fingerprint

Estramustine
Etoposide
Prostatic Neoplasms
Hormones
Appointments and Schedules
Vinca Alkaloids
Vinblastine
vinorelbine
Bone Diseases
Prostate-Specific Antigen
Neutropenia
Disease Progression
Anemia
Confidence Intervals
Neoplasm Metastasis
Bone and Bones

Keywords

  • Chemotherapy
  • Estramustine
  • Etoposide
  • Prostate cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. / Colleoni, Marco; Graiff, C.; Vicario, G.; Nelli, P.; Sgarbossa, G.; Pancheri, F.; Manente, P.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 20, No. 4, 08.1997, p. 383-386.

Research output: Contribution to journalArticle

Colleoni, Marco ; Graiff, C. ; Vicario, G. ; Nelli, P. ; Sgarbossa, G. ; Pancheri, F. ; Manente, P. / Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1997 ; Vol. 20, No. 4. pp. 383-386.
@article{2759c973d2d6461d94f9595a43b806b3,
title = "Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer",
abstract = "Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy. Encouraging results have been reported in Phase II studies with estramustine associated with vinblastine or etoposide. Vinorelbine is a new semisynthetic vinca alkaloid that has demonstrated activity in prostate cancer. We therefore evaluated the activity of the following schedule: estramustine, 400 mg/m2 orally days 1-42; etoposide, 50 mg/m2 orally days 1-14; and 28-42; vinorelbine, 20 mg/m2 days 1, 8, 28, and 35; cycles being repeated every 8 weeks. Twenty-five patients have been included and are assessable for response and side effects. Patient characteristics were as follows: median age, 71 years (range 55-81); ECOG performance status 0-2; nonosseous disease, 3 cases; bone metastases, 23 cases. Sixty-two cycles have been delivered. Two patients with measurable disease and six patients with bone disease had a partial remission for an overall response rate of 32{\%} (95{\%} confidence interval 15-53{\%}). Seven patients had stabilization of disease and 10 had progression of disease. Median duration of response was 3 months (range 2-5). Prostate-specific antigen in 14 patients (56{\%}) decreased from baseline by at least 50{\%}. Toxicity was manageable. Neutropenia was mild, with only three cases of grade Ill-IV toxicity. Two patients had severe anemia. The results of this study indicate that the schedule is active and well tolerated in hormone-refractory prostate cancer patients.",
keywords = "Chemotherapy, Estramustine, Etoposide, Prostate cancer, Vinorelbine",
author = "Marco Colleoni and C. Graiff and G. Vicario and P. Nelli and G. Sgarbossa and F. Pancheri and P. Manente",
year = "1997",
month = "8",
doi = "10.1097/00000421-199708000-00013",
language = "English",
volume = "20",
pages = "383--386",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

AU - Colleoni, Marco

AU - Graiff, C.

AU - Vicario, G.

AU - Nelli, P.

AU - Sgarbossa, G.

AU - Pancheri, F.

AU - Manente, P.

PY - 1997/8

Y1 - 1997/8

N2 - Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy. Encouraging results have been reported in Phase II studies with estramustine associated with vinblastine or etoposide. Vinorelbine is a new semisynthetic vinca alkaloid that has demonstrated activity in prostate cancer. We therefore evaluated the activity of the following schedule: estramustine, 400 mg/m2 orally days 1-42; etoposide, 50 mg/m2 orally days 1-14; and 28-42; vinorelbine, 20 mg/m2 days 1, 8, 28, and 35; cycles being repeated every 8 weeks. Twenty-five patients have been included and are assessable for response and side effects. Patient characteristics were as follows: median age, 71 years (range 55-81); ECOG performance status 0-2; nonosseous disease, 3 cases; bone metastases, 23 cases. Sixty-two cycles have been delivered. Two patients with measurable disease and six patients with bone disease had a partial remission for an overall response rate of 32% (95% confidence interval 15-53%). Seven patients had stabilization of disease and 10 had progression of disease. Median duration of response was 3 months (range 2-5). Prostate-specific antigen in 14 patients (56%) decreased from baseline by at least 50%. Toxicity was manageable. Neutropenia was mild, with only three cases of grade Ill-IV toxicity. Two patients had severe anemia. The results of this study indicate that the schedule is active and well tolerated in hormone-refractory prostate cancer patients.

AB - Hormone-refractory prostate cancer is characterized by a low response rate following second-line therapy. Encouraging results have been reported in Phase II studies with estramustine associated with vinblastine or etoposide. Vinorelbine is a new semisynthetic vinca alkaloid that has demonstrated activity in prostate cancer. We therefore evaluated the activity of the following schedule: estramustine, 400 mg/m2 orally days 1-42; etoposide, 50 mg/m2 orally days 1-14; and 28-42; vinorelbine, 20 mg/m2 days 1, 8, 28, and 35; cycles being repeated every 8 weeks. Twenty-five patients have been included and are assessable for response and side effects. Patient characteristics were as follows: median age, 71 years (range 55-81); ECOG performance status 0-2; nonosseous disease, 3 cases; bone metastases, 23 cases. Sixty-two cycles have been delivered. Two patients with measurable disease and six patients with bone disease had a partial remission for an overall response rate of 32% (95% confidence interval 15-53%). Seven patients had stabilization of disease and 10 had progression of disease. Median duration of response was 3 months (range 2-5). Prostate-specific antigen in 14 patients (56%) decreased from baseline by at least 50%. Toxicity was manageable. Neutropenia was mild, with only three cases of grade Ill-IV toxicity. Two patients had severe anemia. The results of this study indicate that the schedule is active and well tolerated in hormone-refractory prostate cancer patients.

KW - Chemotherapy

KW - Estramustine

KW - Etoposide

KW - Prostate cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0030835839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030835839&partnerID=8YFLogxK

U2 - 10.1097/00000421-199708000-00013

DO - 10.1097/00000421-199708000-00013

M3 - Article

VL - 20

SP - 383

EP - 386

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -